Current Medical Research and Opinion · 2024 · 16 citations · 10 references
PharmacyInternal MedicinePharmacoeconomicsClinical EpidemiologyPharmacoeconomic ModelingResource Utilization AnalysisComorbidityDirect Medical CostsHealth Care CostsHealthcare Cost AnalysisMyasthenia GravisResource Utilization MeasurementBurden Of Illness AnalysisBurden Of Illness AssessmentBurden Of Illness MeasurementDisease Burden ComparisonEconomic Burden Of DiseaseEconomic Burden Of IllnessIncremental CostsPatient Financial Burden Analysis
Introduction: This study assessed incremental healthcare costs and resource utilization (HRU) associated with generalized myasthenia gravis (gMG) as well as variability in these outcomes among patients with gMG and common comorbidities and acute MG-related events. Methods: Adults with gMG and without MG were identified from a large US database (2017–2021). The index date was the first MG diagnosis (gMG cohort) or random date (non-MG cohort). Cohorts were propensity score matched 1:1. The gMG cohort included subgroups of patients with a 12-month pre-index (baseline) cardiometabolic or psychiatric comorbidity, or a post-index MG exacerbation/crisis. Monthly healthcare costs (2021 USD) and HRU were compared post-index between gMG and non-MG cohorts. Results: The gMG and matched non-MG cohorts each contained 2,739 patients. Mean incremental healthcare costs associated with MG were $4,155 (gMG: $5,567; non-MG: $1,411), with differences driven by incremental inpatient cost of $2,166 (gMG: $2,617; non-MG: $452); all p < 0.001. The gMG versus non-MG cohort had 4.36 times more inpatient admissions and 2.26 times more outpatient visits; all p < 0.001.Among patients with gMG in cardiometabolic (n = 1,859), psychiatric (n = 1,308), and exacerbation/crisis (n = 419) subgroups, mean monthly healthcare costs were $6,660, $7,443, and $17,330, respectively.Conclusions: gMG is associated with substantial incremental costs and HRU, with inpatient costs driving the total incremental costs. Costs increased by 20% and 34% among patients with cardiometabolic and psychiatric conditions, respectively, and over 3 times among those with acute MG-related events. gMG is a complex disease requiring management of comorbidities and treatment options that can prevent acute symptomatic events.
10
A study of comorbidities in myasthenia gravis
U. K. Misra, Jayantee Kalita, Varun Kumar Singh et al. · Acta Neurologica Belgica · 2019 · 68 citations · Full text
Cost analysis of myasthenia gravis from a large U.S. insurance database
Jeffrey T. Guptill, Alexander Marano, Andrew Krueger et al. · Muscle & Nerve · 2011 · 49 citations
Estimated cost of treating myasthenia gravis in an insured U.S. population
Jeffery T. Guptill, Bal Krishan Sharma, Alex Marano et al. · Muscle & Nerve · 2011 · 47 citations